Controlled Drug Theft Leads to Investigator Warning Letter

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

Controlled Drug Theft Leads to Investigator Warning Letter

J.W. Schomisch

May 10, 2024 at 10:52 AM EST

A clinical investigator in Tamarac, Florida, received a May 2 Warning Letter from the FDA Center for Drug Evaluation and Research for allegedly failing to take adequate precautions to prevent theft or diversion of an investigational drug that was subject to the Controlled Substances Act (21 C.F.R. §312.69). According to the Warning Letter, the clinical investigator, Dr. Kevin... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

Controlled Drug Theft Leads to Investigator Warning Letter

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT